DURGA-4

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
508 patients (estimated)
Tags
CAR T Cell, CD19, B-Cell Maturation Antigen (BCMA), Randomization
Trial Type
Treatment
Last Update
SparkCures ID
2221
NCT Identifier
NCT07391657

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.